XML 21 R5.htm IDEA: XBRL DOCUMENT v3.25.4
Consolidated Statements of Operations - USD ($)
$ in Thousands
 12 Months Ended
Dec. 31, 2025
Dec. 31, 2024
Income Statement [Abstract]    
Research and development (“R&D”) expenses, net $ 21,292 $ 24,663
General and administrative expenses 9,628 11,776
Gain from early lease termination (2,949)
Goodwill impairment 801
IPR&D impairment 11,842 3,237
Other long-lived assets impairment 1,653 4,046
Operating loss 41,466 44,523
Other expense (income) 93 (2,143)
Interest expenses 20 873
Finance expense , net 724 919
Income from change in fair value of warrants (6,111) (26,458)
Loss before tax 36,192 17,714
Tax expenses 7 13
Net Loss $ 36,199 $ 17,727
Basic loss per share of Common Stock (in Dollars per share) $ 22.19 $ 25.37
Diluted loss per share of Common Stock (in Dollars per share) $ 22.19 $ 58.31
Weighted average number of shares used in computing basic loss per share of Common Stock (in Shares) [1] 1,631,037 698,870
Weighted average number of shares used in computing diluted loss per share of Common Stock (in Shares) [1] 1,631,037 757,749
[1] All share amounts have been retroactively adjusted to reflect a 1-for-19 reverse share split as discussed in Note 12A.